MRK logo

Merck & Company Inc. (MRK)

$143.37

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MRK

Market cap

$353.44B

EPS

0.97

P/E ratio

116.4

Price to sales

5.4

Dividend yield

2.371%

Beta

0.13111

Price on MRK

Previous close

$144.46

Today's open

$143.32

Day's range

$142.31 - $144.89

52 week range

$92.11 - $156.92

Profile about MRK

CEO

Robert M. Davis

Employees

75000

Headquarters

Rahway, NJ

Exchange

New York Stock Exchange

Shares outstanding

2.47B

Issue type

Common Stock

MRK industries and sectors

Healthcare

Pharmaceuticals

News on MRK

Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director

RAHWAY, N.J.--(BUSINESS WIRE)--Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director.

news source

Business Wire • 11 hours ago

news preview

Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?

MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.

news source

Zacks Investment Research • 6 hours ago

news preview

Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?

MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers.

news source

Zacks Investment Research • 2 hours ago

news preview

Merck stops trials of blood cancer drug after risk assessment

Merck said on Tuesday it would stop development of its experimental blood cancer drug, nemtabrutinib, after a ​review found the treatment's benefits may not outweigh the ‌risks.

news source

Reuters • Nov 17, 2026

news preview

Merck Announces First-Quarter 2027 Dividend

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2027 Dividend.

news source

Business Wire • Nov 17, 2026

news preview

Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development program evaluating nemtabrutinib (MK-1026), an investigational, oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. Nemtabrutinib is being evaluated for patients with chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and other hematologic malignancies in the BELLWAVE program. Merck is discontinuing the.

news source

Business Wire • Nov 17, 2026

news preview

Is Merck's Stock Still a Good Buy at $150?

Merck is coming off a strong quarter as revenue from a new version of Keytruda boosted its top line. It remains likely, however, that its revenue will drop off in the near future as key patents on Keytruda are expiring in the near future.

news source

The Motley Fool • Nov 16, 2026

news preview

Summit Crumbles After FDA Rejects Merck-Rivaling Lung Cancer Drug

Summit Therapeutics stock crashed Monday after the Food and Drug Administration rejected its Merck-rivaling lung cancer drug, ivonescimab.

news source

Investors Business Daily • Nov 16, 2026

news preview

Nike Among 13 Dividend Growth Companies To Announce Annual Dividend Increases In Latter Half Of November

I expect Nike (NKE) to raise its dividend 1.2–2.4%, as weak sales, flat EPS and a payout ratio around 80% constrain growth. Matthews International (MATW) risks a dividend cut; Hormel (HRL) faces an above-100% payout ratio and likely will increase its annual dividend just one cent. Motorola Solutions (MSI) should deliver a 10%+ increase, while Marzetti (MZTI) is poised to extend its 63-year streak with a roughly 5% boost.

news source

Seeking Alpha • Nov 16, 2026

news preview

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of WELIREG® (belzutifan), Merck's first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus lenvatinib, the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult p.

news source

Business Wire • Nov 13, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Merck & Company Inc.

Open an M1 investment account to buy and sell Merck & Company Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MRK on M1